Author: Customer Service

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026.Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences...

Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) — Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) today issues this statement regarding the ongoing investigation in Vietnam related to the ONUS Pro cryptocurrency platform (the “Platform”). The Company today learned of the indictments of Nhan (“Eric”) Vuong, Chairman of the Company’s Board of Directors, and Chien Tran, a member of the Company’s Board of Directors, through the official announcement by Vietnam’s Ministry of Public Security (the “MPS”) and Vietnamese news media, simultaneously with the general public. Prior to today, the Company had received no official communication from any authorities, law enforcement, or regulatory agencies in any jurisdiction regarding this matter. The Company...

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that the Company has granted, in the aggregate, 477,535 restricted share units (“RSUs”) and 32,738 deferred share units (“DSUs”) to directors and officers of the Company. The RSUs and DSUs granted to directors are scheduled to vest on a one-third per annum basis over a three-year period. The RSUs granted to officers are based on a combination of time and performance with 50% of the RSUs vesting 1/3 on the anniversary of the grant date over a period of three years and 50% of the RSUs vesting on the third anniversary of the grant date subject to achievement of certain key performance indicators as established by the Company’s Board of Directors. Each vested RSU entitles the holder to receive one share of the Company’s common stock...

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George...

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders Amsterdam, March 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced the resolutions to be submitted for adoption at the Annual General Meeting of Shareholders (AGM) which will be held in Amsterdam, the Netherlands, on May 27, 2026. The resolutions, proposed by the Supervisory Board, are:The adoption of the Company’s statutory annual accounts for the year ended December 31, 2025, prepared in accordance with International Financial Reporting Standards (IFRS). The 2025 statutory annual accounts1 were filed with the Netherlands Authority for the Financial Markets (AFM) on March 26, 2026 and are posted on the Company’s website...

SALT LAKE CITY, March 26, 2026 (GLOBE NEWSWIRE) — Datacentrex, Inc. (Nasdaq: DTCX) (“Datacentrex” or the “Company”), a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses, today announced the pricing of its confidentially marketed public offering (the “Offering”) of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, at a public offering price of $2.00 per share (inclusive of the pre-funded warrant exercise price). The Company expects to receive aggregate gross proceeds of $20.17 million from the Offering, before deducting placement agent fees and other related expenses. The Offering is expected to close on or about March 30,...

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD :The 2025 annual financial report; The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial...

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — Firan Technology Group Corporation (TSX: FTG) (OTCQX: FTGFF) (“FTG”) will release the first quarter 2026 financial results after the market closes on Wednesday, April 8, 2026. The Corporation will host a live conference call on Thursday, April 9, 2026, at 8:30am (Eastern Time) to discuss the first quarter of 2026 financial results. Anyone wishing to participate in the call should dial 289-514-5100 or 1-800-717-1738, Conference ID 33073, and identify that you are calling to participate in the FTG conference call. The Chairperson is Mr. Brad Bourne. A replay of the call will be available until May 11, 2026, and will be available on the FTG website at www.ftgcorp.com. The number to call for a rebroadcast is 289-819-1325 or 1-888-660-6264, Playback Passcode 33073. ABOUT FIRAN TECHNOLOGY GROUP...